News | April 06, 2009

Lantheus Acquires Rights to MRA Contrast Agent for Peripheral Vascular Imaging

April 7, 2009 - Lantheus Medical Imaging Inc. has acquired the U.S., Canadian and Australian rights to MS-325 (formerly marketed as VASOVIST, gadofosveset trisodium, by Bayer Schering Pharma) from EPIX Pharmaceuticals.

In December 2008, EPIX received FDA marketing approval for the magnetic resonance angiography (MRA) agent MS-325 to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease. Currently, there are no other imaging agents approved for MRA in the U.S.

Under the terms of the agreement, Lantheus acquired the U.S. (including Puerto Rico), Canadian, and Australian rights to MS-325 from EPIX. EPIX will continue to own European and other ex-U.S. rights for the imaging agent. Lantheus is planning to launch MS-325 under a different name before the year-end.

MS-325 is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through MRA. MS-325 has been approved for marketing in the U.S. and in 37 countries outside the U.S.

For more information: www.lantheus.com.

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals| May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals| May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Overlay Init